MediGene AG · LS:A40ESG
MediGene — Q2 2009 Earnings Presentation
12 slides from MediGene's earnings presentation, Aug 7, 2009
Slide 1: Earnings call Q2/2009
Earnings call Q2/2009 Munich, August 7, 2009 Dr. Frank Mathias, CEO Dr. Thomas Klaue, CFO Dr. Axel Mescheder, CDO & CSO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intents", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Overview
Overview Dr. Frank Mathias
Slide 4: Important steps made in the first half year
Important steps made in the first half year Start of sales promotion and active marketing of Veregen® in the USA through MediGene's partner Nycomed US regulatory authority grants orphan drug designation for EndoTAGTM-1 Marketing partnership agreement concluded for commercialization of Veregen®
Slide 5: Encouraging promotion of Veregen in the US
Encouraging promotion of Veregen® in the US about 600 prescriptions / month (June 2009) 90% are new prescriptions Æ Nycomed will further increase promotional efforts X5
Slide 6: EndoTAG-1 partnering ongoing
EndoTAGTM-1 partnering ongoing Still very happy with progress made ASCO Meeting has been successfull for us Partnering process in advanced negotiation status Still committed to conclude the best possible deal Phase II trial in breast cancer (TRNBC) on track Preparation of phase III trial
Slide 7: Financials
Financials Dr. Thomas Klaue
Slide 8: Financials Q2 2009
Financials Q2 2009 In million € Q2-2009 Q2-2008 Change Total revenue 8,374 8,778 -5 % Cost of sales -6,910 -6,576 5% Gross profit 1,464 2,202 -34 % Operating expenses -6,064 -9,474 -42 % EBITDA -4,922 -8,923 -45 % Operating result -5,128 -9,250 -45 % Taxes 0 335 - Net loss for the period -6,383 -7,7
Slide 9: Financial results six months 2009
Financial results six months 2009 In million € 6M 2009 6M 2008 Change Total revenue 19,988 13,767 45 % Cost of sales -14,528 -9,972 46 % Gross profit 5,460 3,795 44 % Operating expenses -12,656 -20,927 -40 % EBITDA -6,782 -16,477 -59 % Operating result -7,196 -17,132 -58 % Taxes 0 1000 Net loss for
Slide 10: Outlook and financial forecast 2009
Outlook and financial forecast 2009: Product revenues further up, losses further down Average monthly cash burn rate for the remaining 6 months 2009 app. € 1,5 million Further revenue growth driven by Eligard® and Veregen® Cost cuttings launched in 2008 become fully effective Operating losse
Slide 11: Q&A
Q&A
Slide 12: MediGene AG contact details
MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com MediGene Ltd. 57c Milton Park Abingdon, Oxon, OX14 4RX United Kingdom Phone: +44 1235 438600 Fax: +44 1235 438601 MediGene Inc. 10660 Scripps Ranch Blvd., Suite 200